Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Journal of Clinical Pharmacy and Therapeutics
|
January 24, 2008
Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists
F Vroom, M A J F van de Laar, E N van Roon, et al.
Respiratory Medicine
|
September 27, 2023
The perceived waning of biologics in severe asthma
J A Kroes, L H G Van Hal, L Van Dijk, et al.
Annals of the Rheumatic Diseases
|
January 16, 2007
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study
J M van Woerkom, A A Kruize, R Geenen, et al.
Annals of the Rheumatic Diseases
|
July 18, 2008
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M K Reinders, C Haagsma, T L Th A Jansen, et al.
European Journal of Clinical Pharmacology
|
March 5, 2017
The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study
B E Oortgiesen, E N van Roon, P Joosten, et al.
British Journal of Clinical Pharmacology
|
August 27, 2005
Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation
E N van Roon, M Hoekstra, H Tobi, et al.
British Journal of Clinical Pharmacology
|
July 17, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice
E N Van Roon, T L Th A Jansen, L Mourad, et al.
British Journal of Clinical Pharmacology
|
May 21, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice
E N Van Roon, T L Th A Jansen, L Mourad, et al.
Annals of the Rheumatic Diseases
|
September 4, 2004
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
E N van Roon, T L T A Jansen, M A F J van de Laar, et al.
Annals of the Rheumatic Diseases
|
February 6, 2008
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
M K Reinders, E N van Roon, T L Th A Jansen, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Journal of Clinical Pharmacy and Therapeutics
|
January 24, 2008
Treatment of pregnant and non-pregnant rheumatic patients: a survey among Dutch rheumatologists
F Vroom, M A J F van de Laar, E N van Roon, et al.
Respiratory Medicine
|
September 27, 2023
The perceived waning of biologics in severe asthma
J A Kroes, L H G Van Hal, L Van Dijk, et al.
Annals of the Rheumatic Diseases
|
January 16, 2007
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study
J M van Woerkom, A A Kruize, R Geenen, et al.
Annals of the Rheumatic Diseases
|
July 18, 2008
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M K Reinders, C Haagsma, T L Th A Jansen, et al.
European Journal of Clinical Pharmacology
|
March 5, 2017
The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study
B E Oortgiesen, E N van Roon, P Joosten, et al.
British Journal of Clinical Pharmacology
|
August 27, 2005
Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation
E N van Roon, M Hoekstra, H Tobi, et al.
British Journal of Clinical Pharmacology
|
July 17, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice
E N Van Roon, T L Th A Jansen, L Mourad, et al.
British Journal of Clinical Pharmacology
|
May 21, 2004
Leflunomide in active rheumatoid arthritis: a prospective study in daily practice
E N Van Roon, T L Th A Jansen, L Mourad, et al.
Annals of the Rheumatic Diseases
|
September 4, 2004
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
E N van Roon, T L T A Jansen, M A F J van de Laar, et al.
Annals of the Rheumatic Diseases
|
February 6, 2008
Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol
M K Reinders, E N van Roon, T L Th A Jansen, et al.
Page
of 5